Effect of Smoking on Clinical Prognosis in Male Patients With Acute Coronary Syndrome After Drug-eluting Stent Therapy
10.3969/j.issn.1000-3614.2015.07.004
- VernacularTitle:男性急性冠状动脉综合征患者药物洗脱支架治疗后吸烟状态对临床预后的影响
- Author:
Jun LIU
;
Kangning ZHU
;
Zhongyu ZHU
;
Chuanyu GAO
;
Xianpei WANG
;
Jie KOU
;
You ZHANG
;
Datun QI
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Drug-eluting stent;
Smoking status;
Prognosis
- From:
Chinese Circulation Journal
2015;(7):631-634
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the compliance of smoking cessation and the effect of smoking status on long-term clinical prognosis in male patients with acute coronary syndrome (ACS) after drug-eluting stent (DES) therapy. Methods: A total of 656 ACS patients after DES therapy were studied, according to the post-operative smoking status, the patients were divided into 3 groups: Non-smoking group,n=226, Quit smoking group,n=283 and Persistent smoking group, n=147. The patients were followed-up for the average of 27 months, the major adverse cardio-/cerebral-vascular events (MACCE) were recorded in detail, and the effect of smoking status for MACCE occurrence were evaluated by multivariable Cox regression analysis. Results: The pre-operative smoking rate was 65.5% (430/656) of patients and post-operative smoking rate was 22.4% (147/656). Compared with Non-smoking group and Quit smoking group, the patients in Persistent smoking group had the younger age (P<0.001), more patients with abnormal blood lipids (P=0.005) and having lower level of education (P<0.001). The all cause death rates in Non-smoking group, Quit smoking group and Persistent smoking group were at 1.8%, 1.1% and 6.1% respectively,P=0.004; the MACCE occurrence rates were at 7.1%, 5.3% and 15.0% respectively,P=0.002. Multivariable Cox regression analysis showed that post-operative smoking was the independent risk factor for MACCE occurrence, HR =1.404, 95% CI (1.206-1.793),P=0.008. Conclusion: Smoking is the independent risk factor for MACCE occurrence in male ACS patients after DES therapy.
